[
    [
        {
            "time": "",
            "original_text": "北上资金全透视月报：上月外资大幅流出 加仓周期减持消费 减持股份",
            "features": {
                "keywords": [
                    "北上资金",
                    "外资流出",
                    "加仓周期",
                    "减持消费"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "金融",
                    "消费"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "北上资金全透视月报：上月外资大幅流出 加仓周期减持消费 减持股份",
                "Correlation": 5,
                "Sentiment": 4,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 3,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "【异动股】泰格医药(03347-HK)涨3.9%",
            "features": {
                "keywords": [
                    "泰格医药",
                    "股价上涨"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【异动股】泰格医药(03347-HK)涨3.9%",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 5,
                "Impact": 6,
                "Duration": 4,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "港股异动︱泰格医药(03347)涨超4% 获瑞银首予“买入”并预期今年收入可同比增13%",
            "features": {
                "keywords": [
                    "泰格医药",
                    "股价上涨",
                    "瑞银",
                    "买入评级",
                    "收入增长"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "港股异动︱泰格医药(03347)涨超4% 获瑞银首予“买入”并预期今年收入可同比增13%",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "医药生物行业月报：医药板块调整或近尾声",
            "features": {
                "keywords": [
                    "医药生物",
                    "板块调整",
                    "尾声"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药生物行业月报：医药板块调整或近尾声",
                "Correlation": 4,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 7,
                "Entity_Density": 2,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 5,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "瑞银：预期今年收入同比增13% 首予泰格医药(03347)“买入”评级",
            "features": {
                "keywords": [
                    "瑞银",
                    "收入增长",
                    "泰格医药",
                    "买入评级"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "瑞银：预期今年收入同比增13% 首予泰格医药(03347)“买入”评级",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "瑞银：首予泰格医药“买入”评级，目标价149港元",
            "features": {
                "keywords": [
                    "瑞银",
                    "买入评级",
                    "泰格医药",
                    "目标价"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "瑞银：首予泰格医药“买入”评级，目标价149港元",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "瑞银：首予泰格医药(3347.HK)“买入”评级目标价149港元",
            "features": {
                "keywords": [
                    "瑞银",
                    "买入评级",
                    "泰格医药",
                    "目标价"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "瑞银：首予泰格医药(3347.HK)“买入”评级目标价149港元",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        }
    ]
]